Researchers at IVAC, WHO and CEPI, in partnership with the Asian Development bank have released several new briefs including two summarizing findings on the effectiveness of COVID-19 vaccines in children and the effectiveness of COVID-19 viral vector vaccines.
In children, the mRNA vaccines provide good protection against severe disease and inactivated provide moderate protection though some declines are seen by six months, while protection against symptomatic disease and infection of any severity is lower and decreases quickly.
Protection against Omicron variant symptomatic disease of any severity ranges from low to moderate while protection is higher against severe disease but declines somewhat over six months. A booster shot (3rd dose) gives 63% protection initially which declines to around 40% after four months, and protection against severe disease is higher at 92%, declining only slightly to 86% by four months.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.